Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction

Pál Pacher, Lucas Liaudet, Péter Bai, Jon G. Mabley, Pawel M. Kaminski, László Virág, Amitabha Deb, Éva Szabó, Zoltán Ungvári, Michael S. Wolin, John T. Groves, Csaba Szabo

Research output: Contribution to journalArticle

235 Citations (Scopus)

Abstract

Background - Increased oxidative stress and dysregulation of nitric oxide have been implicated in the cardiotoxicity of doxorubicin (DOX), a commonly used antitumor agent. Peroxynitrite is a reactive oxidant produced from nitric oxide and superoxide in various forms of cardiac injury. Using a novel metalloporphyrinic peroxynitrite decomposition catalyst, FP15, and nitric oxide synthase inhibitors or knockout mice, we now delineate the pathogenetic role of peroxynitrite in rodent models of DOX-induced cardiac dysfunction. Methods and Results - Mice received a single injection of DOX (25 mg/kg IP). Five days after DOX administration, left ventricular performance was significantly depressed, and high mortality was noted. Treatment with FP15 and an inducible nitric oxide synthase inhibitor, aminoguanidine, reduced DOX-induced mortality and improved cardiac function. Genetic deletion of the inducible nitric oxide synthase gene was also accompanied by better preservation of cardiac performance, In contrast, inhibition of the endothelial isoform of nitric oxide synthase with N-nitro-L-arginine methyl ester increased DOX-induced mortality. FP15 reduced the DOX-induced increase in serum LDH and creatine kinase activities. Furthermore, FP15 prevented the DOX-induced increase in lipid peroxidation, nitrotyrosine formation, and metalloproteinase activation in the heart but not NAD(P)H-driven superoxide generation. Peroxynitrite neutralization did not interfere with the antitumor effect of DOX. FP15 also decreased ischemic injury in rats and improved cardiac function and survival of mice in a chronic model of DOX-induced cardiotoxicity. Conclusions - Thus, peroxynitrite plays a key role in the pathogenesis of DOX-induced cardiac failure. Targeting peroxynitrite formation may represent a new cardioprotective strategy after DOX exposure or in other conditions associated with peroxynitrite formation, including myocardial ischemia/reperfusion injury.

Original languageEnglish (US)
Pages (from-to)896-904
Number of pages9
JournalCirculation
Volume107
Issue number6
DOIs
StatePublished - Feb 16 2003
Externally publishedYes

Fingerprint

Metalloporphyrins
Peroxynitrous Acid
Doxorubicin
Nitric Oxide Synthase Type II
Superoxides
Mortality
Nitric Oxide
Myocardial Reperfusion Injury
Nitric Oxide Synthase Type III
Wounds and Injuries
Metalloproteases
Creatine Kinase
Reperfusion Injury
Oxidants
Knockout Mice
Nitric Oxide Synthase
Antineoplastic Agents
NAD
Lipid Peroxidation
Myocardial Ischemia

Keywords

  • Cardiac function
  • Doxorubicin
  • Heart failure
  • Nitric oxide
  • Oxidative stress

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction. / Pacher, Pál; Liaudet, Lucas; Bai, Péter; Mabley, Jon G.; Kaminski, Pawel M.; Virág, László; Deb, Amitabha; Szabó, Éva; Ungvári, Zoltán; Wolin, Michael S.; Groves, John T.; Szabo, Csaba.

In: Circulation, Vol. 107, No. 6, 16.02.2003, p. 896-904.

Research output: Contribution to journalArticle

Pacher, P, Liaudet, L, Bai, P, Mabley, JG, Kaminski, PM, Virág, L, Deb, A, Szabó, É, Ungvári, Z, Wolin, MS, Groves, JT & Szabo, C 2003, 'Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction', Circulation, vol. 107, no. 6, pp. 896-904. https://doi.org/10.1161/01.CIR.0000048192.52098.DD
Pacher, Pál ; Liaudet, Lucas ; Bai, Péter ; Mabley, Jon G. ; Kaminski, Pawel M. ; Virág, László ; Deb, Amitabha ; Szabó, Éva ; Ungvári, Zoltán ; Wolin, Michael S. ; Groves, John T. ; Szabo, Csaba. / Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction. In: Circulation. 2003 ; Vol. 107, No. 6. pp. 896-904.
@article{ec3413b01bd349ac9423176053c17f98,
title = "Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction",
abstract = "Background - Increased oxidative stress and dysregulation of nitric oxide have been implicated in the cardiotoxicity of doxorubicin (DOX), a commonly used antitumor agent. Peroxynitrite is a reactive oxidant produced from nitric oxide and superoxide in various forms of cardiac injury. Using a novel metalloporphyrinic peroxynitrite decomposition catalyst, FP15, and nitric oxide synthase inhibitors or knockout mice, we now delineate the pathogenetic role of peroxynitrite in rodent models of DOX-induced cardiac dysfunction. Methods and Results - Mice received a single injection of DOX (25 mg/kg IP). Five days after DOX administration, left ventricular performance was significantly depressed, and high mortality was noted. Treatment with FP15 and an inducible nitric oxide synthase inhibitor, aminoguanidine, reduced DOX-induced mortality and improved cardiac function. Genetic deletion of the inducible nitric oxide synthase gene was also accompanied by better preservation of cardiac performance, In contrast, inhibition of the endothelial isoform of nitric oxide synthase with N-nitro-L-arginine methyl ester increased DOX-induced mortality. FP15 reduced the DOX-induced increase in serum LDH and creatine kinase activities. Furthermore, FP15 prevented the DOX-induced increase in lipid peroxidation, nitrotyrosine formation, and metalloproteinase activation in the heart but not NAD(P)H-driven superoxide generation. Peroxynitrite neutralization did not interfere with the antitumor effect of DOX. FP15 also decreased ischemic injury in rats and improved cardiac function and survival of mice in a chronic model of DOX-induced cardiotoxicity. Conclusions - Thus, peroxynitrite plays a key role in the pathogenesis of DOX-induced cardiac failure. Targeting peroxynitrite formation may represent a new cardioprotective strategy after DOX exposure or in other conditions associated with peroxynitrite formation, including myocardial ischemia/reperfusion injury.",
keywords = "Cardiac function, Doxorubicin, Heart failure, Nitric oxide, Oxidative stress",
author = "P{\'a}l Pacher and Lucas Liaudet and P{\'e}ter Bai and Mabley, {Jon G.} and Kaminski, {Pawel M.} and L{\'a}szl{\'o} Vir{\'a}g and Amitabha Deb and {\'E}va Szab{\'o} and Zolt{\'a}n Ungv{\'a}ri and Wolin, {Michael S.} and Groves, {John T.} and Csaba Szabo",
year = "2003",
month = "2",
day = "16",
doi = "10.1161/01.CIR.0000048192.52098.DD",
language = "English (US)",
volume = "107",
pages = "896--904",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction

AU - Pacher, Pál

AU - Liaudet, Lucas

AU - Bai, Péter

AU - Mabley, Jon G.

AU - Kaminski, Pawel M.

AU - Virág, László

AU - Deb, Amitabha

AU - Szabó, Éva

AU - Ungvári, Zoltán

AU - Wolin, Michael S.

AU - Groves, John T.

AU - Szabo, Csaba

PY - 2003/2/16

Y1 - 2003/2/16

N2 - Background - Increased oxidative stress and dysregulation of nitric oxide have been implicated in the cardiotoxicity of doxorubicin (DOX), a commonly used antitumor agent. Peroxynitrite is a reactive oxidant produced from nitric oxide and superoxide in various forms of cardiac injury. Using a novel metalloporphyrinic peroxynitrite decomposition catalyst, FP15, and nitric oxide synthase inhibitors or knockout mice, we now delineate the pathogenetic role of peroxynitrite in rodent models of DOX-induced cardiac dysfunction. Methods and Results - Mice received a single injection of DOX (25 mg/kg IP). Five days after DOX administration, left ventricular performance was significantly depressed, and high mortality was noted. Treatment with FP15 and an inducible nitric oxide synthase inhibitor, aminoguanidine, reduced DOX-induced mortality and improved cardiac function. Genetic deletion of the inducible nitric oxide synthase gene was also accompanied by better preservation of cardiac performance, In contrast, inhibition of the endothelial isoform of nitric oxide synthase with N-nitro-L-arginine methyl ester increased DOX-induced mortality. FP15 reduced the DOX-induced increase in serum LDH and creatine kinase activities. Furthermore, FP15 prevented the DOX-induced increase in lipid peroxidation, nitrotyrosine formation, and metalloproteinase activation in the heart but not NAD(P)H-driven superoxide generation. Peroxynitrite neutralization did not interfere with the antitumor effect of DOX. FP15 also decreased ischemic injury in rats and improved cardiac function and survival of mice in a chronic model of DOX-induced cardiotoxicity. Conclusions - Thus, peroxynitrite plays a key role in the pathogenesis of DOX-induced cardiac failure. Targeting peroxynitrite formation may represent a new cardioprotective strategy after DOX exposure or in other conditions associated with peroxynitrite formation, including myocardial ischemia/reperfusion injury.

AB - Background - Increased oxidative stress and dysregulation of nitric oxide have been implicated in the cardiotoxicity of doxorubicin (DOX), a commonly used antitumor agent. Peroxynitrite is a reactive oxidant produced from nitric oxide and superoxide in various forms of cardiac injury. Using a novel metalloporphyrinic peroxynitrite decomposition catalyst, FP15, and nitric oxide synthase inhibitors or knockout mice, we now delineate the pathogenetic role of peroxynitrite in rodent models of DOX-induced cardiac dysfunction. Methods and Results - Mice received a single injection of DOX (25 mg/kg IP). Five days after DOX administration, left ventricular performance was significantly depressed, and high mortality was noted. Treatment with FP15 and an inducible nitric oxide synthase inhibitor, aminoguanidine, reduced DOX-induced mortality and improved cardiac function. Genetic deletion of the inducible nitric oxide synthase gene was also accompanied by better preservation of cardiac performance, In contrast, inhibition of the endothelial isoform of nitric oxide synthase with N-nitro-L-arginine methyl ester increased DOX-induced mortality. FP15 reduced the DOX-induced increase in serum LDH and creatine kinase activities. Furthermore, FP15 prevented the DOX-induced increase in lipid peroxidation, nitrotyrosine formation, and metalloproteinase activation in the heart but not NAD(P)H-driven superoxide generation. Peroxynitrite neutralization did not interfere with the antitumor effect of DOX. FP15 also decreased ischemic injury in rats and improved cardiac function and survival of mice in a chronic model of DOX-induced cardiotoxicity. Conclusions - Thus, peroxynitrite plays a key role in the pathogenesis of DOX-induced cardiac failure. Targeting peroxynitrite formation may represent a new cardioprotective strategy after DOX exposure or in other conditions associated with peroxynitrite formation, including myocardial ischemia/reperfusion injury.

KW - Cardiac function

KW - Doxorubicin

KW - Heart failure

KW - Nitric oxide

KW - Oxidative stress

UR - http://www.scopus.com/inward/record.url?scp=0037448784&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037448784&partnerID=8YFLogxK

U2 - 10.1161/01.CIR.0000048192.52098.DD

DO - 10.1161/01.CIR.0000048192.52098.DD

M3 - Article

VL - 107

SP - 896

EP - 904

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 6

ER -